Dr. Stephen J. Schuster, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 231
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
PA license MD027079E -
Internal Medicine Physician
PA license MD027079E
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Penn Presbyterian Medical Center Philadelphia, PA
- Chester County Hospital West Chester, PA
- Lancaster General Hospital Lancaster, PA
- Pennsylvania Hospital Philadelphia, PA
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 231
- Services billed
- 996
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 228 | 134 |
| Established patient office or other outpatient visit, 20-29 minutes | 204 | 141 |
| Telephone medical discussion with physician, 11-20 minutes | 41 | 19 |
| Established patient office or other outpatient visit, 10-19 minutes | 19 | 18 |
| Telephone medical discussion with physician, 5-10 minutes | 18 | 11 |
| Established patient office or other outpatient visit, 40-54 minutes | 17 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Philadelphia, PA | 21 |
| Jaypirca (pirtobrutinib) | 19 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Philadelphia, PA | 18 |
| Calquence (acalabrutinib maleate) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 30 payments worth $22,705 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $7,540 |
|---|---|
| AbbVie Inc. | $5,425 |
| Chugai Pharmaceutical Co., LTD. | $3,449 |
| Beigene USA, Inc. | $3,000 |
| Janssen Global Services, LLC | $2,025 |
| Novartis Pharmaceuticals Corporation | $340 |
| Adc Therapeutics America, Inc. | $218 |
| Genentech USA, Inc. | $212 |
| Consulting Fee | $20,115 |
|---|---|
| Food and Beverage | $1,695 |
| Travel and Lodging | $894 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Feb 20, 2025 | Consulting Fee | $7,380 |
| Beigene USA, Inc. Jan 31, 2025 | Consulting Fee BRUKINSA · Oncology | $3,000 |
| AbbVie Inc. Jan 8, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $3,000 |
| Chugai Pharmaceutical Co., LTD. Jun 19, 2025 | Consulting Fee | $2,460 |
| AbbVie Inc. Jan 8, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,250 |
| Janssen Global Services, LLC Jan 20, 2025 | Consulting Fee | $2,025 |
| Chugai Pharmaceutical Co., LTD. Jun 19, 2025 | Travel and Lodging travel to Lugano, Switzerland | $894 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $236,864 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Celgene Corporation · Active, not recruiting · NCT04245839 - Chronic Lymphocytic Leukemia (CLL)
AstraZeneca Pharmaceuticals LP - A Modular Phase II, Single-arm, Multicenter, Open-label study to evaluate the Efficacy and Safety of AZD0486 in Subjects with Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)
AstraZeneca Pharmaceuticals LP - An open-label, multicenter, phase i/ii trial evaluating the safety, efficacy, and pharmacokinetics of escalating doses of mosunetuzumab (BTCT4465A) as a single agent and combined with atezolizumab in patients with rel…
Genentech, Inc. - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
Celgene Corporation - An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Celgene Corporation - Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene Corporation · Recruiting · NCT03435796 - Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Kite Pharma, Inc. - Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel
Kite Pharma, Inc. - CAR T Followed by Bispecific Antibodies
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.